Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Lobular Carcinoma In Situ: early-phase trial registry
5 of 7 indexed Breast Lobular Carcinoma In Situ trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Breast Lobular Carcinoma In Situ: 7 US clinical trials tracked, 5 recruiting.
Breast Lobular Carcinoma In Situ is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition breast-lobular-carcinoma-in-situ
OPEN 5 | RECR 71% | LATE 0 | EARLY 4 | RANK #2497 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)
Breast Lobular Carcinoma In Situ lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Lobular Carcinoma In Situ on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Lobular Carcinoma In Situ is recruiting above its size-band peers.
5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Breast Lobular Carcinoma In Situ research.
National Cancer Institute (NCI) accounts for 4 of 7 trials (57.1%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Breast Lobular Carcinoma In Situ trials plan to enrol fewer than 100 people.
Median target enrolment is 66 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Breast Lobular Carcinoma In Situ research is mostly interventional.
5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Ohio State University Comprehensive Cancer Center
NCT05178498
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
NCT06184750
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
NCT05941520
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
NCT06195306
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
Mayo Clinic
NCT05755269
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
National Cancer Institute (NCI)
NCT03317405
EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05086705
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Lobular Carcinoma In Situ records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Lobular Carcinoma In Situ trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Lobular Carcinoma In Situ page
7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Breast Lobular Carcinoma In Situ trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Breast Lobular Carcinoma In Situ trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Lobular Carcinoma In Situ condition card totals 7 registered trials; most-linked intervention Questionnaire Administration; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.